The 13 linked references in paper A. Komarov L., А. КОМАРОВ Л. (2015) “ОЦЕНКА ЧУВСТВИТЕЛЬНОСТИ К КЛОПИДОГРЕЛУ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ // EVALUATION OF SENSITIVITY TO CLOPIDOGREL: THE CURRENT STATE OF THE PROBLEM” / spz:neicon:aterotromboz:y:2015:i:2:p:95-106

  1. 2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal doi:10.1093/eurheartj/ehu278. (the paper at Socionet)
  2. 2013 ACCF/AHA Guideline for the Management of STElevation Myocardial Infarction. JACC,61, 4: 78–140.
  3. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012, 33: 2569–2619 doi:10.1093/eurheartj/ehs215.
  4. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation European Heart Journal doi:10.1093/eurheartj/ehv320.
  5. Aradi D, Storey RF, Komocsi A et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal, 2014, 35, 209–215 doi:10.1093/eurheartj/eht375.
  6. Hulot J, Collet J, Silvain J et al. Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration: A Systematic Meta-Analysis.J Am Coll Cardiol,2010, Jul 6, 56(2): 134-43. doi: 10.1016/j.jacc.2009.12.071.
  7. Bonaca MP, Bhatt DL, Cohen M et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. DOI: 10.1056/NEJMoa1500857.
  8. Aradi D, Komуcsi A, Price MJ et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol,2013. Sep 1. 167(5): 2140–8. doi: 10.1016/j.ijcard.2012.05.100.
  9. Price MJ, Berger PB, Teirstein PS et al. Standard- vs highdose clopidogrel based on platelet function testing after percutaneouscoronary intervention: the GRAVITAS randomized trial. JAMA, 2011. Mar 16, 305(11): 1097-105. doi: 10.1001/jama.2011. 290.
  10. Aradi D, Tornyos A, Pinter T et al. Optimizing P2Y-receptor inhibition in acute coronary syndrome patients based on platelet function testing: impact of prasugrel and highdose clopidogrel. J Am Coll Cardiol, 2014, Mar 25, 63(11): 1061–70. doi: 10.1016/j.jacc.2013.12.023.
  11. Гуськова Е.В., Панченко Е.П., Комаров А.Л., Добровольский А.Б., Самко А.Н. Остаточная реактивность тромбоцитов к АДФ и риск кровотечений у больных стабильной ИБС, получающих двойную антитромбоцитарную терапию в связи с плановым чрескожным коронарным вмешательством.
  12. Karve AM, Seth M, Sharma M. Contemporary Use of Ticagrelor in Interventional Practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium). Am J Cardiol, 2015. Jun 1.и 115(11): 1502-6. doi: 10.1016/j.amjcard. 2015.02.049.
  13. S Gandhi, B Zile, M K. Tan. Increased Uptake of Guideline Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome Reflective. Canadian Journal of Cardiology, 2014. doi: 10.1016/j.cjca. 2014.09.011.